Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Sanofi Finds Ideal 'Partner' For Leukine

Executive Summary

Partner Therapeutics takes on Sanofi's immunostimulant. Novartis transitions struggling Arzerra for compassionate use only outside the US, with compensation to Genmab, while Shire licenses I.V. immunoglobulin candidate from AB Biosciences.

Advertisement

Related Content

Interview: Sandoz CEO On Biosimilars And Reshaping US Business
Shire May Split Up – But Punting On Bigger Decisions For Now
Shire Tempts Busch From Bayer As It Eyes Top Spot In Rare Diseases
Novel Regeneron Deal Puts Partner Decibel In The Driver's Seat
No Smoke Without Fire: Unichem Divests Domestic Business To Torrent
SpringWorks Launches With $103m, Four Pfizer Drugs And A Focus On Underserved Patients
Puma's Nerlynx Scores Broad Label Across Adjuvant Breast Cancer Subgroups
J&J’s $30bn For Actelion Buys Immediate And Longer-Term Value
Sun Starts Integration Of GSK's Opiates Business
BARDA seeks Amgen's Neupogen, Sanofi's Leukine for nuke attack countermeasures

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC100302

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel